FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

People tend to like their Medicare Advantage plans — until they don’t. Consider the case of Rose LaChapelle, who says the Medicare Advantage plan that was supposed to provide care for her 92 ...

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

In a report released on January 24, David Low from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...